0.7032
0.06%
0.0004
Handel nachbörslich:
.71
0.0068
+0.97%
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market 2024 To Reach $2.33 Billion By 2028 At Rate Of - EIN News
X4 Pharmaceuticals Inc Inc. (XFOR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Top investors say X4 Pharmaceuticals Inc (XFOR) ticks everything they need - SETE News
Unitedhealth Group Inc [UNH] Stock sold by Insider ROOS THOMAS E for $1.62 million - Knox Daily
Should investors be concerned about X4 Pharmaceuticals Inc (XFOR)? - US Post News
Market Watch: X4 Pharmaceuticals Inc (XFOR)’s Noteworthy Gain, Closing at 0.71 - The Dwinnex
Biopharma Layoff Tracker 2024: Oncternal, Biosense Webster, Charles River Laboratories and More Cut Staff - BioSpace
United States Intravenous Iron Drug Market By Application - Third Eye News
North America Medulloblastoma Drug Market By Application – news - Vaccine Storage & Packaging ...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by TD Asset Management Inc - Defense World
North America Drug Discovery Outsourcing Market Size USD 3.4 Bn in 2023| CAGR of 7.2%| USD 5.93 Bn by 2032 - Third Eye News
FDA advisers unconvinced by Intercept's liver disease drug benefits, safety - Reuters
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with - The Bakersfield Californian
Alkem joins $3 bn race for JB Chem as Torrent pauses talks - The Economic Times
North America Addictions Therapeutics Market By Application - Third Eye News
United States 1,3-Dioxane-4-Aceticacid, 6-(Cyanomethyl)-2,2-Dimethyl-, 1,1-Dimethylethyl Ester, (4R,6R) Market Size, Share, Growth & Forecast – Third Eye News - Third Eye News
You might want to take a look at X4 Pharmaceuticals Inc (XFOR) now - SETE News
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - Chronicle-Tribune
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
X4 Pharmaceuticals Inc (XFOR) stock on the rise: An overview - US Post News
BMRN: Undervalued Biotech Stocks Ready for a Breakout - StockNews.com
Pharmaceutical Intermediates Market Size To Reach USD 14.0 - GlobeNewswire
Ratios Revealed: Decoding X4 Pharmaceuticals Inc (XFOR)’s Financial Health - The Dwinnex
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO - StockTitan
Anosmia Market Innovations Investigated by Size, Share, Industry Analysis, Segments And Forecast To 2033 - WhaTech
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules - StockTitan
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market 2024 - openPR
X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 1.3% - MarketBeat
The time has not yet come to remove your chips from the table: X4 Pharmaceuticals Inc (XFOR) - SETE News
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - Quantisnow
EVP Research Swayze Eric acquired $425 worth of shares (11 units at $38.64), increasing direct ownership by 0.03% to 34,907 units (SEC Form 4) - Quantisnow
Amendment: EVP, Finance & CFO Hougen Elizabeth L sold $107,105 worth of shares (2,162 units at $49.54), decreasing direct ownership by 2% to 92,868 units (SEC Form 4) - Quantisnow
Potential Price Increase for Opendoor Technologies Inc (OPEN) After Recent Insider Activity - Knox Daily
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
EVP, Chief Development Officer Geary Richard S sold $32,159 worth of shares (651 units at $49.40), decreasing direct ownership by 0.76% to 84,823 units (SEC Form 4) - Quantisnow
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Trading Day Review: X4 Pharmaceuticals Inc (XFOR) Gains Momentum, Closing at 0.70 - The Dwinnex
X4 Pharmaceuticals Inc (XFOR)’s stock rises to 0.70 per share - US Post News
Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech
Alpha Methyldopa Market Advancements Highlighted by Size, Share, Growth, Trends and Industry Forecast (2024... - WhaTech
mRNA Cancer Vaccines And Therapeutics Global Market In The New Analysis By Leading Research Firm - WhaTech
Top 10 pharma companies in India by market cap - Forbes India
North America Drug for Organ Rejection Prophylaxis Market By Application : A Global Perspective on Regional Markets - அக்னி செய்திகள்
Coccidioidomycosis Drug Market Size, Market Resilience in Times of Disruption (2024-2034) - Cineglit
Coccidioidomycosis Drug Market Size, Market Resilience in Times of Disruption (2024-2034) - அக்னி செய்திகள்
North America Pharmaceutical Grade Apixaban Market By Application : Industry Analysis and Forecast 2031 - அக்னி செய்திகள்
Recursion Pharmaceuticals To Acquire Exscientia In $688 Million Deal - Finimize
North America Pharmaceutical Grade Dapagliflozin Market By Application : Size, Trends, Share and Forecast 2031 - அக்னி செய்திகள்
Gen X Is So Unprepared For Retirement They're Being Called 'Silver Squatters' Because 1 in 5 Are Counting On Help From Their Kids - Yahoo Finance
Global Ketolides Market 2024 Report Explores By Size, Drivers, Trends, Competitors - WhaTech
Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference - Quantisnow
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences - StockTitan
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - BioSpace
Ionis to present at upcoming investor conferences - Quantisnow
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates – Company Announcement - Financial Times
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences - Yahoo Finance
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Declines By 45.4% - Defense World
Malignant Melanoma Treatment Market Size, Demand, Share, Trends, Forecast To 2033 - WhaTech
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Size, Share, Growth, Trends and Forecast 20... - WhaTech
Candidiasis Therapeutics Market Innovations Investigated by Size, Analysis, Trends, Opportunities And Strat... - WhaTech
Did X4 Pharmaceuticals Inc (XFOR) perform well in the last session? - US Post News
Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower - Simply Wall St
Investor’s Toolkit: Key Ratios for Assessing X4 Pharmaceuticals Inc (XFOR)’s Performance - The Dwinnex
Peptide Based Metabolic Disorders Therapeutics Market Report Probes the Demand, Analysis, and Outlook 2024-... - WhaTech
What is X4 Pharmaceuticals Inc (XFOR) Stock Return on Shareholders’ Capital? - SETE News
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma - Yahoo Finance
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics - StockTitan
Drug Screening Laboratory Service Market Size & Analysis By 2024 -2029 -Abbott Laboratories (Alere Inc.), Mayo Clinic Laboratories, Que – அக்னி செய்திகள் - அக்னி செய்திகள்
President & CEO Lian Brian exercised 1,000 shares at a strike of $7.77 and sold $69,900 worth of shares (1,000 units at $69.90) (SEC Form 4) - Quantisnow
Director Singleton J Matthew exercised 5,700 shares at a strike of $1.19 and sold $397,430 worth of shares (5,700 units at $69.72) (SEC Form 4) - Quantisnow
Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower - Simply Wall St
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):